NYU Langone Health
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, NYU Langone Health sits in the top decile of US sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count).
NYU Langone Health: 1,164 sponsored US clinical trials, 197 recruiting.
NYU Langone Health sponsors 1,164 registered US clinical trials on ClinicalTrials.gov, 197 of them currently recruiting, and 741 completed. 123 of these trials are in Phase 3-4 (later-stage) and 231 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 12 trials.
Top-decile sponsor footprint
NYU Langone Health ranks in the top decile of sponsors by registered trial count (#25 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
741 of 866 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (85.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,164 total, page 1 of 24
Improving Cryoablation Efficacy With BARRigel Rectal Spacing (ICE-BARR)
NCT07567027
tDCS: Sleep to Mood in Depression (S2M-D)
NCT07572526
PlayReadVIP in Family Child Care
NCT07489079
Elacestrant in Advanced Triple Positive Breast Cancer
NCT07612215
Adaptability of an Undetectable = Untransmissible Model for HBV
NCT07449091
Aspirin Dosing in Pregnancy
NCT07525635
ctDNA-guided Addition of Ipilimumab to Patients Receiving Nivolumab and Relatlimab
NCT07504796
Evaluating the Effectiveness of a Colonoscopy Surveillance Recommendations Algorithm in Clinical Practice
NCT07658716
Biomarkers for Exercise
NCT07340281
Hippocampal Oscillations During Exploration
NCT07224191
Pilot Testing of a Colorectal Cancer Education Program
NCT07361614
Activity Tracking, Care Partner Co-participation, Text Reminders, Instructional Education, Video-Guided Physical Rehabilitation, and Exercise
NCT07321587
Gut Microbiome Pill
NCT07243756
Obstructive Sleep Apnea Therapeutic Intervention for REsiDual Sleepiness
NCT06698809
tPBM in Older Adults With Traumatic Brain Injury
NCT06956404
Stress and Anxiety Effects on Valuation
NCT07252947
Psilocybin for Opioid Use Disorder (OUD)
NCT06796062
Immunosuppressant Management in Rheumatology Patients Undergoing Elective Total Shoulder Arthroplasty
NCT07138898
ED Diabetes Screening and Outpatient Care
NCT05899023
DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer
NCT07249372
The Young Adults' Experiences With Virtual Reality (YAES VR) Study
NCT06917391
RS-tDCS for Cannabis Use Disorder: The C.A.R.E.S. Initiative
NCT07184983
Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas
NCT06829173
Novel Digital Patient-Reported Outcomes Tool for Diabetes Management
NCT05884775
NIRS Monitoring in the NICU and AKI
NCT07222722
Care in Multiple Sclerosis (MS)
NCT07011914
Catch A Vibe - 24-00864
NCT07116629
Extra-cochlear Electrode Placement at the Post-auricular Vagus Nerve in Cochlear Implantation
NCT07011927
Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
NCT06927024
Prospective Evaluation of Silk Fibroin Incision Dressings in ACL Reconstruction
NCT07217613
PRISM Study: Prostate Recurrence Detection Using Imaging With PSMA PET/MRI Post-high Intensity Focused Ultrasound
NCT07184970
Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction
NCT06961630
Time Restricted Eating for WeIght LoSs MainTenance-2
NCT07190170
Community Safety and Violence
NCT07494019
NYU Epilepsy Self-Management Study
NCT07087821
Intent of Surgery for IPMN
NCT07216521
Effects of Belzutifan on 89Zr-DFO-girentuximab PET Uptake in Patients With Renal Cell Carcinoma (RCC)
NCT07179770
Enhancing Engagement of Partners in Research
NCT07166913
Stuttering and Neuromodulation
NCT07222163
Implementation of Communication Disability Collection and Accommodations in Primary Care Settings
NCT07656584
Neurobehavioral Mechanisms of Psilocybin-assisted Treatment for AUD
NCT06349083
Noninvasive Vagal Nerve Stimulation
NCT06816004
Feasibility of Home-Based Intermittent 60Hz Light Therapy for Major Depressive Disorder (MDD)
NCT07111390
Trial Evaluating the Safety and Efficacy Of MR-Linac-Guided Radiotherapy as Salvage Treatment After External Beam Radiotherapy Recurrence (TUMORNATOR II)
NCT07142967
Home-Based Transcranial Direct Current Stimulation (tDCS) for Depression in Multiple Sclerosis (MS)
NCT06901687
Paired Vagus Nerve Stimulation Mechanisms
NCT06716112
The Effect of Peri-Operative Adjunctive Probiotics on Immunological Markers in Cases of Prosthetic Joint Infection of the Hip and Knee
NCT06919913
Identifying Strategies to Reduce Cardiovascular Risk Among Mothers of Young Children
NCT06796075
Breast Cancer Implementation Science Study With Educational Intervention
NCT06927895
Shelter HArm Reduction Evaluation
NCT07170072
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 99 |
| Phase 2 | 132 |
| Phase 3 | 28 |
| Phase 4 | 95 |
Therapeutic Areas
What is open in the NYU Langone Health pipeline
197 recruiting of 1,164 indexed (17% open); 741 completed (64%).
Phase mix: 123 late (III/IV) vs 231 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (12 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
NYU Langone Health: open-pipeline peers nationwide
Peers matched on 1,164 registered trials and 17% open enrollment, not the therapeutic-area sidebar.
NYU Langone Health sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,164 trials (± recruiting share)
- University of Alabama at Birmingham · 1,160 trials · 19% recruiting
- Wake Forest University Health Sciences · 1,140 trials · 15% recruiting
- Emory University · 1,208 trials · 17% recruiting
- Northwestern University · 1,209 trials · 15% recruiting
Sponsors near 17% open enrollment (± trial volume)
- CSL Behring · 17% recruiting · 71 trials
- Penn State University · 17% recruiting · 219 trials
- University of Hawaii · 17% recruiting · 77 trials
- University of Utah · 17% recruiting · 818 trials
Related
What to do with this NYU Langone Health page
1,164 registered trials is a research-attention snapshot, not an endorsement of NYU Langone Health or any single study.
- 197 of NYU Langone Health's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition NYU Langone Health studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
NYU Langone Health pipeline card: 1,164 registered trials from official public datasets.Report a data error.